Trials / Withdrawn
WithdrawnNCT04532554
Growth Hormone in Obese Cases With Covid-19
The Impact of Growth Hormone in Obese Cases With Covid-19
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- ClinAmygate · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The use of growth hormone in obese cases with COVID-19 may help them to recover earlier.
Detailed description
It is well known that lymphoid organs such the thymus, the spleen and peripheral blood produce growth hormone (GH) and GH receptor is expressed on different subpopulations of lymphocytes. Many in vitro and in animal studies demonstrate an important role of GH in immunoregulation. GH stimulates T and B cells proliferation and immunoglobulin synthesis, enhances the maturation of myeloid progenitor cells and is also able to modulate cytokine response. The use of growth hormone in obese cases with COVID-19 may help them to recover earlier.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Growth Hormone | Recombinant growth hormone will be used |
| DRUG | Placebo | Saline injection with the same amount |
Timeline
- Start date
- 2020-10-26
- Primary completion
- 2020-12-10
- Completion
- 2020-12-20
- First posted
- 2020-08-31
- Last updated
- 2020-09-16
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04532554. Inclusion in this directory is not an endorsement.